KR102062357B1 - 헬리코박터 파일로리 치료용 약제학적 조성물 - Google Patents

헬리코박터 파일로리 치료용 약제학적 조성물 Download PDF

Info

Publication number
KR102062357B1
KR102062357B1 KR1020157023788A KR20157023788A KR102062357B1 KR 102062357 B1 KR102062357 B1 KR 102062357B1 KR 1020157023788 A KR1020157023788 A KR 1020157023788A KR 20157023788 A KR20157023788 A KR 20157023788A KR 102062357 B1 KR102062357 B1 KR 102062357B1
Authority
KR
South Korea
Prior art keywords
amoxicillin
capsule
omeprazole
rifabutin
dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157023788A
Other languages
English (en)
Korean (ko)
Other versions
KR20150118176A (ko
Inventor
레자 파티
질레드 라데이
가이 골드버그
패트릭 고셀린
Original Assignee
레드힐 바이오파마 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51297592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102062357(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 레드힐 바이오파마 엘티디 filed Critical 레드힐 바이오파마 엘티디
Publication of KR20150118176A publication Critical patent/KR20150118176A/ko
Application granted granted Critical
Publication of KR102062357B1 publication Critical patent/KR102062357B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
KR1020157023788A 2013-02-13 2014-02-12 헬리코박터 파일로리 치료용 약제학적 조성물 Active KR102062357B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361764385P 2013-02-13 2013-02-13
US201361764401P 2013-02-13 2013-02-13
US61/764,385 2013-02-13
US61/764,401 2013-02-13
PCT/US2014/016071 WO2014127025A1 (en) 2013-02-13 2014-02-12 Pharmaceutical compositions for the treatment of helicobacter pylori

Publications (2)

Publication Number Publication Date
KR20150118176A KR20150118176A (ko) 2015-10-21
KR102062357B1 true KR102062357B1 (ko) 2020-01-03

Family

ID=51297592

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157023788A Active KR102062357B1 (ko) 2013-02-13 2014-02-12 헬리코박터 파일로리 치료용 약제학적 조성물

Country Status (26)

Country Link
US (8) US9050263B2 (enExample)
EP (1) EP2956149B1 (enExample)
JP (1) JP6494529B2 (enExample)
KR (1) KR102062357B1 (enExample)
CN (2) CN105163743A (enExample)
AU (1) AU2014216373B2 (enExample)
BR (1) BR112015019264B1 (enExample)
CA (1) CA2900763C (enExample)
CL (1) CL2015002253A1 (enExample)
CY (1) CY1122113T1 (enExample)
DK (1) DK2956149T3 (enExample)
ES (1) ES2744406T3 (enExample)
HK (1) HK1217645A1 (enExample)
HR (1) HRP20191559T1 (enExample)
HU (1) HUE052411T2 (enExample)
IL (1) IL240387B (enExample)
MX (1) MX368536B (enExample)
NZ (1) NZ711754A (enExample)
PH (1) PH12015501783B1 (enExample)
PL (1) PL2956149T3 (enExample)
PT (1) PT2956149T (enExample)
RU (1) RU2671400C2 (enExample)
SG (1) SG11201506318QA (enExample)
SI (1) SI2956149T1 (enExample)
UA (1) UA120249C2 (enExample)
WO (1) WO2014127025A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6494529B2 (ja) 2013-02-13 2019-04-03 レッド ヒル バイオファーマ リミテッドＲｅｄＨｉｌｌ Ｂｉｏｐｈａｒｍａ Ｌｔｄ． ピロリ菌治療用医薬組成物
KR101884230B1 (ko) * 2016-02-29 2018-08-01 주식회사 유영제약 에소메프라졸을 포함하는 제제
JP2018149269A (ja) * 2017-01-18 2018-09-27 マッカイ メディカル ファンデーション ザ プレスビュテロス チャーチ イン タイワン マッカイ メモリアル ホスピタル 消化管感染症に対する管腔内治療システム
NZ754962A (en) * 2017-10-15 2025-11-28 Centre For Digestive Diseases Compositions and methods for treating, ameliorating and preventing h. pylori infections
CN108497546B (zh) * 2018-03-22 2021-03-19 宝可科技（上海）有限公司 一种烟用添加剂及其制备方法和用途
CN110354125A (zh) * 2019-08-12 2019-10-22 珠海赛隆药业股份有限公司 一种治疗幽门螺杆菌感染的组合物及其制剂和用途
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index
KR20230150745A (ko) * 2022-04-22 2023-10-31 한국생명공학연구원 헬리코박터 파일로리에 의한 위 점막 손상 관련 질환의 예방 또는 치료용 약학적 조성물
CN117398360B (zh) * 2023-12-14 2024-03-15 山东齐都药业有限公司 治疗幽门螺杆菌的复方制剂胶囊及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040213847A1 (en) * 2003-04-23 2004-10-28 Matharu Amol Singh Delayed release pharmaceutical compositions containing proton pump inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980637A (en) * 1975-03-17 1976-09-14 Bristol-Myers Company Production of amoxicillin
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
CA2271799A1 (en) 1996-11-22 1998-05-28 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials
SE9700885D0 (sv) 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
AUPP325398A0 (en) * 1998-04-30 1998-05-21 Borody, Thomas J. Improved method for eradicating h. pylori
US5927500A (en) * 1998-06-09 1999-07-27 Milliken & Company Pharmaceutical containment package
JP2000128779A (ja) * 1998-10-20 2000-05-09 Mitsui Chemicals Inc 薬物放出制御型製剤
WO2005048979A2 (en) * 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
EP1803450A1 (en) * 2006-01-03 2007-07-04 Ferrer Internacional, S.A. Pharmaceutical compositions for the eradication of helicobacter pylori
US8383151B2 (en) * 2007-07-06 2013-02-26 Lupin Limited Pharmaceutical compositions of rifaximin
JP5260905B2 (ja) 2007-07-12 2013-08-14 株式会社ジャパンディスプレイ 有機ｅｌ表示装置
CN101755205B (zh) 2007-07-20 2012-01-11 兴和株式会社 铅浓度测定用试剂以及铅浓度测定方法
WO2009017716A2 (en) 2007-07-27 2009-02-05 Depomed, Inc. Pulsatile gastric retentive dosage forms
CN101584681A (zh) * 2008-05-23 2009-11-25 黑龙江福和华星制药集团股份有限公司 一种用于治疗幽门螺旋杆菌感染的片剂胶囊
CN101607086B (zh) * 2009-07-21 2011-11-02 山西安特生物制药股份有限公司 一种复方铋剂组合物及其制备方法
CN102091084B (zh) * 2010-12-09 2012-05-09 王勇 一种复方胶囊及其制备方法
JP6494529B2 (ja) * 2013-02-13 2019-04-03 レッド ヒル バイオファーマ リミテッドＲｅｄＨｉｌｌ Ｂｉｏｐｈａｒｍａ Ｌｔｄ． ピロリ菌治療用医薬組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040213847A1 (en) * 2003-04-23 2004-10-28 Matharu Amol Singh Delayed release pharmaceutical compositions containing proton pump inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Aliment Pharmacol. Ther. Vol. 35, pp941-947 (2012.)
Digestion, Vol. 67, pp1-5 (2003)

Also Published As

Publication number Publication date
BR112015019264B1 (pt) 2021-08-24
IL240387B (en) 2020-02-27
EP2956149A1 (en) 2015-12-23
US10238606B2 (en) 2019-03-26
PH12015501783B1 (en) 2020-02-14
NZ711754A (en) 2020-05-29
RU2015138708A (ru) 2017-03-17
CA2900763A1 (en) 2014-08-21
SG11201506318QA (en) 2015-09-29
US11931463B2 (en) 2024-03-19
HK1217645A1 (zh) 2017-01-20
US20150044283A1 (en) 2015-02-12
KR20150118176A (ko) 2015-10-21
US10898439B2 (en) 2021-01-26
US20140227353A1 (en) 2014-08-14
DK2956149T3 (da) 2019-09-09
EP2956149B1 (en) 2019-06-19
HUE052411T2 (hu) 2021-04-28
AU2014216373B2 (en) 2017-12-21
US20170189341A1 (en) 2017-07-06
WO2014127025A1 (en) 2014-08-21
CY1122113T1 (el) 2020-11-25
US20160235681A1 (en) 2016-08-18
US9050263B2 (en) 2015-06-09
CN105163743A (zh) 2015-12-16
PL2956149T3 (pl) 2020-03-31
SI2956149T1 (sl) 2019-11-29
CL2015002253A1 (es) 2016-07-29
ES2744406T3 (es) 2020-02-25
PT2956149T (pt) 2019-09-20
US11135172B2 (en) 2021-10-05
MX368536B (es) 2019-10-07
CA2900763C (en) 2021-04-06
JP6494529B2 (ja) 2019-04-03
IL240387A0 (en) 2015-09-24
US20240325313A1 (en) 2024-10-03
PH12015501783A1 (en) 2015-12-07
MX2015010490A (es) 2015-10-30
US20190336451A1 (en) 2019-11-07
AU2014216373A1 (en) 2015-08-27
RU2671400C2 (ru) 2018-10-31
UA120249C2 (uk) 2019-11-11
EP2956149A4 (en) 2016-10-12
BR112015019264A2 (pt) 2017-07-18
HRP20191559T1 (hr) 2019-11-29
JP2016508516A (ja) 2016-03-22
US9498445B2 (en) 2016-11-22
BR112015019264A8 (pt) 2019-11-12
US9603806B2 (en) 2017-03-28
US20220062188A1 (en) 2022-03-03
CN109893516A (zh) 2019-06-18
US20190175512A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
KR102062357B1 (ko) 헬리코박터 파일로리 치료용 약제학적 조성물
KR100384961B1 (ko) 프로톤펌프억제제를함유하는다단위제약제제
EP0814840B1 (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent
JPH09511767A (ja) 新規な経口用の医薬使用形態
HUP0101437A2 (hu) Elnyújtott hatóanyag-kibocsátási formájú orális gyógyszerkészítmény
KR20040099265A (ko) 신규의 치환 벤즈이미다졸 제형 및 그 사용방법
MXPA96004354A (en) New form of pharmaceutical dosage or
KR20040047771A (ko) 신규의 치환 벤즈이미다졸 제형 및 그 사용방법
JP2012153712A (ja) 胸やけの処置法
JP2018521137A (ja) 液体剤形中の薬学的活性化合物放出性多層微小粒子
US20240033224A1 (en) Enteric-coated pellet, method for preparing same and formulation comprising same
WO2009137648A1 (en) Multilayer proton pump inhibitor tablets
TWI463998B (zh) Amoxicillin and clomycin have a high absorption rate of pharmaceutical ingredients

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
A302 Request for accelerated examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 7